car-t therapy vs. asct for myeloma
Published 3 years ago • 175 plays • Length 4:29Download video MP4
Download video MP3
Similar videos
-
6:40
car-t vs bispecifics: the best immune approach to replace asct
-
0:48
selecting patients with multiple myeloma for car-t therapy
-
6:38
comparison of the safety & efficacy of car-t therapy vs bispecifics in r/r multiple myeloma
-
0:54
ucartcs1: a novel allogeneic car-t therapy for myeloma
-
3:06
management of multiple myeloma during car-t therapy manufacturing
-
4:04
the future of myeloma treatment and the possibility of cure
-
2:53
understanding how patients relapse from car t-cell therapy
-
6:23
how long will i live with multiple myeloma and is there a cure?
-
1:49
a novel subcutaneous car-t therapy for the treatment of hematological malignancies
-
2:01
car-t updates in myeloma
-
2:52
replacing asct: car-t or bispecific antibodies?
-
1:53
phe885, a t-charge manufactured bcma-directed car-t therapy in r/r myeloma
-
2:35
latest advances in car-t for multiple myeloma: cilta-cel & new car-t platforms
-
2:49
novel strategies to optimize car-t therapy in myeloma
-
4:04
overcoming challenges in car t-cell therapy for multiple myeloma
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
5:56
advances in car-t therapy for r/r multiple myeloma: ide-cel & cilta-cel
-
1:33
patient selection for car-t in all
-
2:18
moving forward: bringing car-t therapy to a frontline setting in myeloma
-
2:22
combining car-ts & bispecific antibodies
-
1:38
challenges of car-t therapy in the real-world setting